The European Medicines Agency issued draft guidelines proposing accelerated study authorization during public‑health emergencies, urging sponsors to work with the EMA’s Emergency Task Force to prioritise well‑designed, multicountry trials over small, isolated programs. The draft addresses participant transfers, adaptive procedures, and safeguards to preserve data integrity while enabling speed. The EMA emphasized that regulatory flexibility must still protect trial participants and data quality. The proposals respond to lessons from the COVID‑19 pandemic and aim to streamline multinational clinical research in crisis settings, potentially shortening timelines for pivotal studies of vaccines and therapeutics during future outbreaks.